Search This Blog

Tuesday, May 20, 2025

NeurAxis FDA Clearance for Treatment of Pediatric FAP/Functional Dyspepsia (FD), Nausea

 Significantly expands IB-Stim’s total addressable market

•   Clearance covers patients aged 8–21

•   Seamless go-to-market strategy with existing reimbursement and provider infrastructure

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has received FDA 510(k) clearance for IB-Stim™ for the treatment of Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia, and FD related Nausea Symptoms, in patients aged 8 to 21 years. This clearance is the second successful expanded FDA indication for IB-Stim, following its initial approval for Functional Abdominal Pain associated with Irritable Bowel Syndrome (IBS). The new indication represents the first treatment ever cleared or approved by the FDA related to functional dyspepsia. It is expected to nearly double the Company’s total addressable market, reinforcing NeurAxis’ leadership in non-invasive, pediatric-focused neuromodulation.

The indication leverages the same CPT code, insurance coverage, and provider call points as the existing IBS indication, supporting a seamless and capital-efficient go-to-market strategy. Commercial rollout for this expanded important indication will begin immediately.

https://finance.yahoo.com/news/neuraxis-awarded-first-ever-fda-120000935.html



No comments:

Post a Comment

Note: Only a member of this blog may post a comment.